CRISPR Therapeutics wins FDA pediatric approval for Casgevy, boosting market potential and pipeline upside despite slow uptake. Click here to read more.

Casgevy also now indicated for transfusion-dependent beta thalassemia in children 2 years ...

The clustered regularly interspaced short palindrome repeats (CRISPR) and Crispr-associated protein 9 (CRISPR/Cas9) is now a well-known, revolutionary method to engineer microbial cells. A key ...

A team of researchers led by Professor Akitsu Hotta (Department of Clinical Application) developed a comprehensive framework ...

Cas9 is directed to its target within the DNA sequence through the use of the guide RNA. A specific sequence of DNA that is between two and five nucleotides in length must align with the 3’ end of the ...

For several years now, the CRISPR/Cas9 gene scissors have been causing a sensation in science and medicine. This new tool of molecular biology has its origins in an ancient bacterial immune system. It ...

Children as young as two with either sickle cell disease or thalassemia are now eligible for the gene therapy.

A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high ...

The company seems to be doing everything it's supposed to be doing; the stock just isn't responding.

The Gene Editing Therapeutics market, driven by advancements in CRISPR technology and precision medicine, presents opportunities in oncology, rare genetic disorders, and chronic diseases. Investment ...